Currently, CEACAM1, CEACAM5, and CEACAM6 are considered as valid prognostic markers and promising therapeutic targets in melanoma, lung, colorectal, and pancreatic cancers [26]. Here, CEACAM5 is linked to familial pancreatic carcinoma.